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Molecular and cellular signatures underlying
superior immunity against Bordetella pertussis
upon pulmonary vaccination
RHM Raeven1,2,6, J Brummelman3,4,6, JLA Pennings5, L van der Maas1, K Helm3, W Tilstra1,
A van der Ark1, A Sloots1, P van der Ley1, W van Eden4, W Jiskoot2, E van Riet1, CACM van Els3,
GFA Kersten1,2, WGH Han3,7 and B Metz1,7
Mucosal immunity is often required for protection against respiratory pathogens but the underlying cellular and
molecularmechanisms of induction remain poorly understood. Here, systems vaccinologywas used to identify immune
signatures after pulmonary or subcutaneous immunization of mice with pertussis outer membrane vesicles. Pulmonary
immunization led to improved protection, exclusively induced mucosal immunoglobulin A (IgA) and T helper type 17
(Th17) responses, and in addition evoked elevated systemic immunoglobulin G (IgG) antibody levels, IgG-producing
plasma cells, memory B cells, and Th17 cells. These adaptive responses were preceded by unique local expression of
genes of the innate immune response related to Th17 (e.g., Rorc) and IgA responses (e.g., Pigr) in addition to local and
systemic secretion of Th1/Th17-promoting cytokines. This comprehensive systems approach identifies the effect of the
administration route on thedevelopment ofmucosal immunity, its importance in protection againstBordetella pertussis,
and reveals potential molecular correlates of vaccine immunity to this reemerging pathogen.
INTRODUCTION
Optimal protection against respiratory pathogens requires
induction of mucosal immunity in the lungs, where tissue-
resident memory T cells1,2 and immunoglobulin A (IgA)
antibodies3 play a pivotal role in the rapid recognition of
pathogens. Therefore, induction of these responses by immu-
nization is appealing. Unfortunately, current vaccines against
respiratory pathogens, including Bordetella pertussis, which
causes whooping cough, do not induce mucosal immunity.
Improvement of pertussis vaccines and optimized vaccination
strategies4,5 are required, as whooping cough persists as an
endemic disease even in highly vaccinated populations.
Acellular pertussis vaccine induces a systemic immune
response characterized by the formation of immunoglobulin
G (IgG) antibodies and a T helper type 2 (Th2)-dominated
response,6–9 whereas a Th1/Th17 response is preferable for
protection against infection.8 Subcutaneous immunization of
outer membrane vesicle pertussis vaccine (omvPV) could be an
improved alternative, as it elicits high serum IgG levels against a
broad antigen range10 and a mixed Th1, Th17, and Th2
response.11 This response is comparable to the response
induced by a B. pertussis infection, but importantly lacks the
mucosal immune responses.8,12–14
Vaccine administration directly into the respiratory tract
provides better protection, compared with intramuscular admin-
istration, because of its induction of local immune responses.15–18
Protection against B. pertussis challenge has been achieved with
various intranasalpertussis vaccinecandidates.19–22However,direct
comparison of local and systemic immune responses induced by
subcutaneous vs. mucosal immunization has not been performed.
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In this study, we used systems vaccinology, a valuable
tool to unravel molecular signatures and predict vaccine
responsiveness,23–26 to investigate in detail how the route of
immunization, i.e., pulmonary vs. subcutaneous, of a pertussis
vaccine candidate affects protection and the quality of immune
responses in mice (Figure 1a). As pertussis vaccine candidate
we used an omvPV prepared from a genetically modified B.
pertussis B1917 strain with retained pertactin (Prn), an
immunogenic virulence factor that is normally cleaved from
the bacterial cell surface.27 The B. pertussis B1917 strain is
phylogenetically relevant to the current circulating strains that
may be responsible for the pertussis resurgence,28 whereas the
enhanced presence of Prnmay favor the detectability of vaccine
antigen-specific cellular immune responses. Besides B. pertussis
clearance from the respiratory tract after intranasal challenge,
we determined gene expression profiles in draining lymph
nodes and lungs, and cytokine profiles and antibody responses
in serum and lungs of immunized mice. Finally, specific B-cell
and T-cell responses were investigated both locally and
systemically. Our results demonstrate innate and adaptive
Figure 1 Study design and Bordetella pertussis colonization measured in the respiratory tract. (a) BALB/c mice were immunized with 1 mg
outer membrane vesicle pertussis vaccine (omvPV) by the pulmonary (PM; red) or subcutaneous (SC; blue) route on days 0 and 28. Subsequently,
for both routes the vaccination-induced responses were characterized over a period of 56 days at 7 time points. In addition, a B. pertussis challenge
(2 105 colony-forming units (CFUs)) was performed on day 56 in both vaccinated groups and nonimmunized (NI) mice (green). Vaccination
responses were characterized at the transcriptomic, proteomic, and cellular levels on given time points, as depicted. (b–d) The number of CFUs
were determined afterB. pertussis challenge in (b) lungs, (c) trachea, and (d) nose lavages of SC, PM, and NImice. #Po0.05 vs. SCmice; þPo0.05 vs.
NI mice.
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hallmarks of superior protective immunity to B. pertussis as
conferred by pulmonary vaccination with omvPV.
RESULTS
Superior protection against B. pertussis infection by
pulmonary compared with subcutaneous omvPV
immunization
Lungs of nonimmunized control mice (NI mice) were heavily
colonized after a B. pertussis challenge with highest numbers
of colony-forming units found 6 days after challenge
(Supplementary Figure S1 online). A dose-dependent
immunization study comparing 1 and 10 mg omvPV
demonstrated that administration of 10 mg omvPV resulted
in complete lung clearance of pulmonary immunizedmice (PM
mice) and most of subcutaneously immunized mice (SC mice)
3 days after challenge. (Supplementary Figure S1).
Immunization with 1 mg revealed that lungs of PM mice
were cleared 4 days after challenge, whereas SC mice were
colonized 3 days longer. Based on these results we decided to
investigate the immunization with 1 mg omvPV for both routes
in more detail in a follow-up study (Figure 1a). The lungs, and
also trachea and noses, were again heavily colonized in NImice
(Figure 1b–d). In contrast,B. pertussiswas againmostly cleared
from lungs of PMmice just 2 days after challenge, whereas those
of SC mice were cleared 5 days later (Figure 1b). In the trachea
of both SC and PM mice, bacteria were mostly cleared 7 days
after challenge (Figure 1c). In the nose, no complete clearance
of B. pertussis was observed in all groups within 28 days after
challenge. However, the number of bacteria in noses of PM
mice was significantly lower than in NI mice 14 days after
challenge (Figure 1d).
Improved humoral responses after PM immunization
Both immunization routes induced high levels of anti-OMV
IgM and IgG antibodies in serum, yet with significantly higher
levels after PM immunization on day 56 (Figure 2a,b). In both
groups, the primary immunization was dominated by IgG1,
whereas the booster immunization showed an increased
contribution of IgG3 (Figure 2c). PM immunization
elicited anti-Prn IgG antibodies only after booster
immunization, whereas they were already observed after
primary SC immunization (Supplementary Figure S2a).
Moreover, booster PM immunization led to increased
values of anti-Prn IgG2a and IgG2b (Supplementary
Figure S2b).
The specificity of anti-OMV IgG antibodies was identified
(Supplementary Figure S3a–c) and revealed antibodies against
12 immunogenic B. pertussis proteins after PM and 17 after
SC immunization (Supplementary Figure S3a,b and
Supplementary Table S1). Of note, this method detects
linear but not conformational epitopes. Nevertheless, the
results indicated a distinct repertoire of antibody specificities
depending on the route of vaccine administration. Spots
showing high staining intensities in both groups corresponded
with proteins BP3755, Vag8, BrkA, and two unidentified
proteins U1–2. Antibodies against AhcY and OmpA(2) were
induced solely by PM immunization, whereas antibody
formation against OmpA(1), BfrG, GroEl, PurH, and two
unidentified proteins (U3–4) were induced solely by SC
immunization. In addition, anti-lipopolysaccharide antibodies
(10 kDa) were produced after booster immunization in
both groups (Supplementary Figure S3c). This anti-
lipopolysaccharide response seems lower compared with the
response described previously with wild-type B1917
omvPV,10,11 most likely because of a lower immunization
dose. Notably, no IgG antibodies could be detected against the
antigens present in acellular pertussis vaccines (Ptx, FHA, and
Fim2/3) except for anti-Prn IgG after omvPV immunization via
either route (data not shown).
IgA antibodies were found exclusively in PM mice in both
serum (Figure 2d) and lungs (Figure 2e). These IgA antibodies
were directed against OMV and Prn (Figure 2d and
Supplementary Figure S2c,d) but not against other
antigens present in acellular vaccines (data not shown).
Anti-OMV IgA in the lung was mainly directed against
Vag8 and lipopolysaccharide (Figure 2e and Supplementary
Figure S3a,d).
At the peak of the plasma cell response (day 35), similar and
modest numbers of anti-OMV and anti-Prn IgG-secreting cells
were found in blood and spleen of PM and SC mice (Figure 2f
and Supplementary Figure S2e). Theywere also detected in the
lungs of PM mice, but not of SC mice. In addition, anti-OMV
and anti-Prn IgA-secreting cells were detected only in the lungs,
spleen, and blood of PM mice (Figure 2f and Supplementary
Figure S2e).With respect to IgG-producingmemory B cells, no
significant difference was detected in spleens of PM or SC mice
(day 56), although a trendwas observed toward higher numbers
in the PM mice (Figure 2g and Supplementary Figure S2f).
Moreover, no anti-OMV and anti-Prn IgA-producing memory
B cells could be detected in all mice.
Overall, the data show that PM immunization induced an
improved B-cell response compared with SC immunization
indicated by increased serum IgM and IgG levels, presence of
pulmonary IgA antibodies, induction of pulmonary IgG-
producing plasma cells, and both systemic and pulmonary IgA-
producing plasma cells.
Enhancedquantity andquality ofCD4þ T-cell responsesby
PM immunization
The magnitude of CD4þ T-cell responses was investigated by
determining the total percentage of B. pertussis-specific
cytokine-producing (interferon-g (IFNg), interleukin (IL)-5,
or IL-17A) CD4þ T cells using intracellular cytokine staining
(ICS) analysis. Both PM and SC immunization induced a
significant increase inOMV-specific andPrn-specific cytokine-
producing CD4þCD44þ T cells already on day 28 (Figure 3a
and Supplementary Figure S4a). On day 56, a significantly
higher percentage of these cells were detected after PM
compared with SC immunization. This difference was also
observed ex vivo at the epitope level, as Prn10-24-specific CD4
þ
T cells were exclusively detected in the blood of PM mice
(Figure 3b).
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Cytokine levels in the culture supernatants of OMV-
stimulated splenocytes revealed that lower levels of Th2
cytokines (IL-4 and IL-5) were secreted by cells from PM
immunized mice as compared with SC immunization
(Supplementary Figure S5a,b). In contrast, increased
production of IL-13 was found (Supplementary Figure
S5b). Moreover, only PM immunization induced specific
IFNg production and caused higher production of IL-17 and
IL-10 (Supplementary Figure S5b). ICS analysis showed a
significantly increased percentage of OMV-specific IFNg-
producing CD4þCD44þ T cells after PM immunization on
day 28 but not at day 56 (Figure 3c). OMV-specific IL-5-
producing CD4þCD44þ T cells were detectable in both PM
and SCmice on days 28 and 56, but were significantly higher in
the SC mice (Figure 3d). OMV-specific IL-17A-producing
CD4þCD44þ T cells were induced after SC immunization
on day 56. Markedly, significantly higher percentages of these
cells were detected after PM immunization at both days 28 and
56 (Figure 3e). A similar trend for Prn-specific CD4þCD44þ
T cells was observed (Supplementary Figure S4b–d). The
distribution of OMV-specific and Prn-specific CD4þCD44þ
T cells, based on the production of IFNg, IL-5, or IL-17A,
indicates that SC immunization induced a Th1-dominated
systemic response on day 28 and a mixed Th1/Th17/Th2
response on day 56 (Figure 3f and Supplementary Figure S4e).
In contrast, PM immunization induced a mixed Th1/Th17
Figure 2 Bordetella pertussis outermembrane vesicle (OMV)-specific B-cell responses induced by pulmonary (PM) and subcutaneous (SC)
immunization with omvPV. (a–e) Anti-OMV (a) immunoglobulin M (IgM), (b) immunoglobulin G (IgG) antibody levels and (c) IgG subclass distribution
were determined in sera. Anti-OMV immunoglobulin A (IgA) antibody levels were determined in (d) sera and (e) lung lysates. Results are expressed as
fluorescence intensities (FI) of 4mice per group per time point. *Po0.05 vs. naivemice (day 0); #Po0.05 vs. SCmice. (f,g) Numbers of (f) OMV-specific
IgG- and IgA-secreting plasma cells in lungs, blood, and spleens and (g) numbers of IgG- and IgA-producingmemory cells in spleenswere determined by
B-cell ELISpot of 6mice per groupat day 35 andday 56, respectively. Results are indicated as antibody-secreting cells (ASCs) per 5105 cells. *Po0.05
vs. naive mice; #Po0.05 vs. SC mice.
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response on day 28 that shifted toward a Th17-dominated
response on day 56.
With respect to mucosal immune responses, OMV-stimulated
lung cells of PMmice revealedmoderate IL-5 andvigorous IL-17A
secretion in supernatant (Figure 3g). In line with this, OMV-
specific IL-17A-producing CD4þCD44þ T cells were solely
detected in PMmice (Figure 3h). Expression of CD103, a marker
for tissue-residentmemoryTcells,was foundon57±24%of these
T cells (data not shown). Moreover, an increased percentage of
pulmonary CD4þCD103þ T cells were detected in PM mice
compared with SC mice and naive mice (Figure 3i).
In conclusion, PM immunization elicits more systemic Th1/
Th17-skewed CD4þ T cells as well as more tissue-resident
Th17 CD4þ T cells compared with SC immunization.
Early cytokine signatures suggest increased Th1 and Th17
responses after PM immunization
Largest differences in cytokine levels were observed 4 h after
primary immunization in serum and lung lysates (Figures 4
and 5). In serum, increased levels of Th1-associated cytokines
CCL4 and CXCL10 were found in both groups, with higher
levels of CXCL10 in SCmice, whereas CCL5 was observed only
in SC mice (Figure 4). IL-5, related to a Th2 response, and
CCL2, related to Th2 and Th17 responses, were observed only
in SC mice. Other Th17-associated cytokines (CXCL1,
granulocyte-colony stimulating factor (G-CSF), IL-6, and
tumor necrosis factor-a (TNFa)) were increased in both
groups, with G-CSF higher in SC mice and IL-6 higher in PM
mice. In addition, IL-10 was enhanced in both groups.
Figure 3 Pulmonary and systemic Bordetella pertussis outer membrane vesicle (OMV)-specific T-cell responses induced by pulmonary
(PM) and subcutaneous (SC) omvPV immunization. (a) Magnitude of the systemic OMV-specific CD4þ T-cell response after 4 days of in vitro
stimulationwithOMVwasdeterminedusing intracellular cytokine staining (ICS) on splenocytes, calculated as the total percentageof cytokine (interleukin
(IL)-5, interferon-g (IFNg), and IL-17A)-producingCD4þCD44þ T cells. (b) Frequency of Prn10–24-specific CD4
þ T cells in bloodwas determined directly
ex vivo on days 28 and 56 (D28 and D56) using a tetramer staining and flow cytometry. (c–e) Percentage of (c) IFNg-, (d) IL-5-, and (e) IL-17-producing
CD4þCD44þ T cells of spleens harvested on days 38 and 56 and stimulated in vitro for 4 days with OMVs. Results of each analysis are given for 6 mice
per group. (f) Distribution of T helper (Th) subsets based on IL-5 (Th2), IFNg (Th1), and IL-17A (Th17) production, as determined by ICS and flow
cytometry. *Po0.05 vs. naive mice; #Po 0.05 vs. SC mice. As determined by multiplex immunoassay (MIA), (g) IL-5 and IL-17A levels in 3-day culture
supernatant of lung cells, isolated on day 56, after in vitro stimulation with OMVs. Results in pgml 1 are corrected for the background level (IMDM
complete medium control) and are given as mean±s.d. of 6 mice per group. (h) Percentage of IL-17-producing CD4þCD44þ T cells in the lungs,
harvested on days 28 and 56, as measured by ICS and flow cytometry after 4 days of in vitro stimulation with OMVs. (i) Flow cytometry for expression of
CD103 on CD4þCD44þ T cells in the lungs on day 56.
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In lung lysates, cytokines associated with a Th1 response
(CCL3, CCL4, CXCL9, CXCL10, IL-12p70), Th2 response
(CCL2, IL-13), and Th17 response (CCL2, CXCL1, CXCL2,
G-CSF, GM-CSF, IL-1b, IL-6, IL-17A, TNFa) as well as CXCL5,
IL-1a, IL-15, LIF, and M-CSF were increased in PM mice
(Figure 5).
Transcriptomic signatures in draining lymph nodes
Microarray analysis on draining lymph nodes (dLNs) from PM
and SC mice, revealed 1,921 differentially expressed genes
(DEGs; pr0.001, fold ratio (FR) Z1.5) compared with naive
mice (Figure 6a). Of these, 951 were upregulated and 466
downregulated exclusively after PM immunization; 109 were
upregulated and 39 were downregulated exclusively after SC
immunization; and 211 were upregulated and 145 were
downregulated in both PM and SC mice. Over-
representation analysis (ORA) indicated enrichment of 141
GO-BP (Gene Ontology Biological Process) terms and KEGG
(Kyoto Encyclopedia of Genes and Genomes) pathways. A
selection of immunologically relevant terms is shown in
Figure 6b.
Genes related to T cells and B cells, based on gene ontology
and text mining, are shown in Figure 6c, d. Many of the 50 T
cell-related genes were associated with distinct Th subsets
(Figure 6c). Upregulation of most genes occurred 4 h after
immunization and from day 7 onwards. More genes were
upregulated in PM mice than in SC mice, including Th17-
associated genes, such as the master regulator for Th17
differentiation (Rorc), Hif1a, and Havcr1. The few T cell-
related genes exclusively expressed in SC mice comprised Th1-
and Th17-associated genes, such as Irf5, Ccr6, and Syt11.
Expression of B cell-related genes in SC mice occurred mainly
on days 7 and 35 (Figure 6d). In contrast, elevated expression of B
cell-related genes occurred earlier in PM mice (4 h after primary
immunization) and persisted until day 28. A smaller number of
genes were induced on day 35 by booster immunization in PM
compared with SC mice. Expression ofMzb1, Ighm, Igkc, Ighg2b,
Jchain, Ighg1, and Aicda suggested antibody production and
presence of B cells in dLN that wasmore pronounced in PMmice.
In addition, upregulation of specific B-cell membrane, activation,
and homing markers were observed. Both immunization routes
induced Cxcr5, Cd22, Cd40, and Cd83 expression, whereas only
the PM route inducedCd38, and only the SC route inducedCd19,
Cd72, Ccr6, and Siglecg.
Many DEGs were found 4 h after PM immunization. They
were mainly involved in cell cycle (data not shown). After SC
immunization, in contrast, only 5% of genes were differentially
expressed after 4 h. Notably, in SC mice 72.5% of the genes
upregulated after 4 hwere regulated by interferons as compared
with 26% in PM mice (Supplementary Figure S6a,b).
Moreover, 50% of these genes in SC mice were regulated
by all three interferons (IFNa, IFNb, and IFNg), whereas the
majority in PM mice were selectively regulated by only one of
the three (Figure 6e and Supplementary Figure S6a,b).
Figure 4 Systemic cytokine responses after pulmonary (PM) and
subcutaneous (SC) outer membrane vesicle pertussis vaccine
(omvPV) immunization. The concentrations of cytokines in serum of
immunized mice were analyzed over time by using multiplex
immunoassay (MIA). Cytokines are grouped based on their association
with aTh1, Th2, or Th17 response.Data are given asmeanconcentrations
for 4 mice per group per time point. *Po0.05 vs. naive mice (day 0);
#Po0.05 vs. SC mice.
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In conclusion, PM and SC immunization with omvPV evoke
distinct innate and adaptive responses in dLN, as detected on
transcriptome level.
Pulmonary transcriptomic signatures
Microarray analysis performed on lung tissue collected during
the primary immunization revealed 691 DEGs (pr0.01, FR
Figure 5 Pulmonary cytokine responses after pulmonary (PM) and subcutaneous (SC) outer membrane vesicle pertussis vaccine (omvPV)
immunization. The concentrations of cytokines in lung lysates of immunized mice were analyzed over time by using multiplex immunoassay (MIA).
Cytokines are grouped based on their association with a Th1, Th2, or Th17 response. The cytokine concentrations were measured in the individual lung
lysates of 4 mice per time point for PM mice and in pooled lung lysates of 4 mice per time point for SC mice.*Po0.05 vs. naive mice (day 0).
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Figure 6 Transcriptomic profiles in the draining lymph nodes (dLNs) following pulmonary (PM) and subcutaneous (SC) outer membrane
vesicle pertussis vaccine (omvPV) immunization. (a–d) Gene expression in PM and SCmice was compared with naive mice (day 0) (fold ratio (FR)
Z1.5,Pr0.001). (a) A total of 1,921genesupregulated (red) or downregulated (green) are visualized in heatmaps (meanofn¼ 3).Genesnot surpassing
a fold change of 1.5 are shown as basal level (black). The overlap (yellow) and the exclusive presence of genes in either the PM (blue) or SC (orange)
immunization groups is depicted next to the heatmap. (b) Over-representation analysis on all 1,921 genes revealed the involvement of specific Gene
OntologyBiological Process (GO-BP) termswith corresponding total amount of genes (blue) andupregulated (red) anddownregulated (green) genes. (c)
T cell-related genes, including association with distinct T helper (Th) subsets. (d) B cell-related genes are depicted for PM and SCmice. (e) The numbers
andpercentagesof genesupregulated in the innate phase (4 h) inPMandSCmiceare comparedwith the Interferomedatabase todetermine involvement
of the type I interferon (IFN; IFNa and IFNb) and/or type II IFN (IFNg) signaling pathway.
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Z2.0) over time compared with naive mice (Figure 7a).
The largest dissimilarity was observed 4 h after PM
immunization, as revealed by principal component analysis
(Figure 7b). Many genes were no longer expressed on or after
day 2, although genes were further upregulated (Figure 7a, b).
Of note, this early transcriptome profile might be a
combination of omvPV-specific and delivery-specific
responses that cannot be distinguished in this data set.
Pulmonary gene expression on day 28 did not return
completely to basal levels. Notably, the lungs of SC mice
also showed some differential gene expression, mainly on day 2
(Figure 7a, b). ORA on the DEGs from PM mice revealed
enrichment of 127 terms (11 KEGG Pathways and 116
GO-BP terms). A selection of these terms is shown in
Figure 7c. Genes involved in pathogen recognition were
reflected by expression of pseudo-response regulator (PRR)
genes, members of corresponding downstream signaling
pathways (inflammasome, TNF, nuclear factor-kB, and
mitogen-activated protein kinase), and effector molecules
(e.g., those representing proinflammatory responses)
(Figure 7c and Supplementary Figure S7a). Moreover,
upregulation was seen in genes expressed in innate
lymphoid cells; genes involved in CSF signaling, T-cell activa-
tion, and humoral response; and genes encoding complement,
cytokines, cytokine receptors, and membrane markers
(Figure 7c and Supplementary Figure S7b).
The pulmonary transcriptomic signatures obtained after PM
immunization were compared with those obtained after
experimental B. pertussis infection (558 genes) from a previous
study12 and revealed 98 overlapping genes. A gene-function
network analysis revealed differences in the involvement of
genes in all five modules investigated: PRR signaling, acute
phase, cytokine response, humoral response, and T-cell
responses (Figure 7d). Notably, the infection data set
comprised more genes related to acute phase and humoral
response, whereas the PM immunization data set included
more genes related to cytokine response and PRR signaling.
Only 27 shared genes were directly connected to the
investigated modules. However, using the STRING
database, 42 additional shared genes could be indirectly
linked to the modules by their interaction with other genes
in the network. A comparison of intensity and kinetics of the
average gene expression of each module revealed that PM
immunization induced faster andmore intense expression of all
modules compared with infection (Figure 7e). In conclusion,
both PM immunization and B. pertussis infection induce
similar modules, but with distinct intensity and kinetics of
expression and involving different genes.
DISCUSSION
PM immunization induces local immunity important for
protection, as demonstrated for several respiratory patho-
gens.16–18 In this study, immune responses evoked by PM and
SC immunization with omvPV were assessed in detail. PM
immunization provided superior protection against B. pertussis
compared with SC immunization, and was associated with
distinct innate and adaptive immune signatures. Only PM
immunization led to the induction of a mucosal immune
response that was indicated by increased gene expression, the
presence of particular cytokines, IgA antibodies, IgA- and IgG-
producing plasma cells, and tissue-resident Th17 cells in the
lungs.Moreover, PM immunization induced a distinct systemic
immune response as compared with SC immunization, with
fewer IFN-regulated genes in the LNs, lower levels of serum
cytokines, and higher serum IgM and IgG levels. PM
immunization also increased numbers of CD4þ T cells, with
a shift in Th subset distribution toward Th17 cells. An overview
of the main findings per immunization route is presented in
Figure 8 and discussed in detail below.
After PM immunization, expression of genes associated with
pathogen recognition was detected in the lungs during the
innate phase (Figure 8a). The expression of Lbp,Cd14, andTlr2
indicate the involvement of Toll-like receptors 2 and 4 (TLR2
and TLR4), similar to what was observed with whole-cell PV
and live bacteria.29–31 Interestingly, Tlr7 and Nlrp3 were
expressed, indicating activation of intracellular PRRs by
omvPV. Subsequently, genes downstream of PRRs, including
MyD88 and nuclear factor-kB, were expressed. Production of
proinflammatory cytokines induced by PRR signaling, such as
IL-1b, IL-6, and CXCL10, occurred in the lungs on gene and
protein levels. Multiple known Th17 effector cytokines13,32 and
Th17-differentiating cytokines were measured in the lungs,
suggesting a Th17-differentiating environment. This was
reflected by the presence of Th17 cells in the dLNs, based
on expression of Rorc, Hif1a, and Havcr1; Th17 cells in the
spleen and, more importantly, tissue-resident Th17 cells in the
lungs. In addition, Th1-associated cytokines33,34 were detected
in the lungs and serum, correlating with subsequent detection
of systemic Th1 cells. This mixed Th1/Th17 response is
considered favorable for providing protection against B.
pertussis infection.8,12,13 In addition, the presence of tissue-
resident T cells in the lungs enhances protection against
respiratory infections.35 The humoral response was character-
ized by pulmonary expression of IgA-related genes, the IgA
transporter (Pigr) and IgA antibodies in lungs and serum. In
line with these findings, IgA-producing plasma cells were
detected in spleen, blood, and lungs. No IgA-secreting memory
B cells were detected in the spleen, most likely because of
homing of these cells to other tissues. High serum IgG levels
corresponded with specific gene expression (Ighg1, Igh2b, and
Jchain) in the dLNs; IgG-producing plasma cells in spleen,
blood, and lungs; and IgG-producing memory B cells in the
spleen. Interestingly, pulmonary expression of Nfil3 and early
expression of Rorc in dLNs suggest involvement of innate
lymphoid cells36 in the immune response upon PM
immunization.
After SC immunization, omvPV is probably recognized in a
similar manner as after PM immunization, mainly through
TLR2 and TLR4, although this was not investigated at the
injection site in this study. The strong systemic cytokine
response reveal a mixed Th1-, Th2-, and Th17-differentiating
environment that was subsequently reflected by presence of
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splenic Th1, Th2, and Th17 cells (Figure 8b). Moreover, the
induction of Th1 cells was linked to the early expression of
genes downstreamof IFN signaling in the dLNs.37 The source of
the early IL-5 production might be type 2 innate lymphoid
cells,36 suggesting their involvement after SC omvPV immu-
nization. Furthermore, expression of B-cell markers (Cd19 and
Cd22) and immunoglobulin-related genes (Igh2b, Jchain, and
Ighg1) revealed the presence of IgG-producing plasma cells in
the dLNs. Accordingly, IgG-producing plasma cells were
detected in spleen and blood, IgG-producing memory B cells
in spleen, and high IgG levels in serum.
The immunity induced by PM omvPV immunization
substantially resembles infection-induced immunity that
remains the benchmark for optimal immunity. Interestingly,
PM omvPV immunization confers protection to a similar
extent as an infection in mice.8,12 Both PM immunization and
Figure 7 Pulmonary transcriptomic profiles following pulmonary (PM) and subcutaneous (SC) outer membrane vesicle pertussis vaccine
(omvPV) immunization. (a–c) Gene expression was compared with naive mice (day 0) (fold ratio (FR) Z2.0, Pr0.01). (a) A total of 691 genes
upregulated (red) or downregulated (green) are visualized in heatmapswith ameanof n¼3 for PMmice and n¼1 (pool of 3mice) for SCmice.Genes not
surpassing a fold ratio of 2.0 are shown as basal level (black). (b) Principal component analysis (PC1 and PC2) shows the (dis)similarity of the five time
points for both PM and SC mice. (c) Over-representation analysis (ORA) on 691 genes revealed involvement of specific Gene Ontology Biological
Process (GO-BP) terms and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways with corresponding total amount (blue), upregulated (red),
and downregulated (green) genes. (d, e) Pulmonary transcriptomes were compared after PM immunization and Bordetella pertussis infection.12 (d) A
gene-function network analysis showing the connection of genes expressed within 28 days after PM immunization/infection to a specific module (blue
line) based on involvement in acute phase, cytokine response, humoral response, pathogen recognition receptor (PRR) signaling, and T-cell responses.
Genes expressed in both data sets (shared, triangle, purple), exclusively expressed in infectedmice (circle, green), or exclusively expressed in PMmice
(circle, red) are depicted. In addition, indirect linkage of shared genes with other genes in the network (gray line) by using the STRING database are
shown. (e) For infectedmice (9 time points) andPMmice (6 time points), an average fold ratio (expressed as LN-transformed numbers) was calculated to
determine the expression intensity and kinetics for each module corresponding to those included in the network analysis.
Figure 8 Overview of the immune responses after pulmonary (PM) and subcutaneous (SC) outer membrane vesicle pertussis vaccine
(omvPV) immunization. Based on the results obtained in this study, themain findings of the innate and adaptive immune responseswere connected for
(a) PM immunization and (b) SC immunization.
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B. pertussis infection induce a pulmonary IgA response.
Moreover, the pulmonary and systemic CD4þ T-cell responses
are similar and Th17 dominated.8,12,13
Still, considerable differences were found between PM
immunization and infection-induced immunity. Serum IgG
and pulmonary IgA levels seem higher after the booster omvPV
PM immunization compared with the levels observed 56 days
after infection;10,14 however, direct side-by-side studies are
required to confirm this. Compared with infection, the omvPV
immunization in general evoked a distinct IgG subclass
response caused in part by high anti-lipopolysaccharide
IgG3 induction after the booster immunization. IgG subclass
distribution is considered indirect evidence for Th
responses.38–40 In our study, the Th responses are not mirrored
in the IgG subclass responses, as the Th responses are
comparable after PM immunization and infection, whereas
the IgG subclass distribution is distinct. As both SC and PM
administration of omvPV result in a comparable IgG subclass
response, the differences compared with infection probably
reflect vaccine composition and vaccination scheme, not the
administration route. Furthermore, the current and previous
study10 together demonstrate that distinct antigen composition
likely explains the difference between antigen specificity of
serum IgG induced by PM immunization vs. infection.
Whereas omvPV contains mainly outer membrane and
periplasmic proteins, live bacteria comprise additional cyto-
solic proteins and are capable of de novo production and
secretion of antigens, such as pertussis toxin (Ptx),10 or antigens
expressed only when infecting a host and not during cultivation
for vaccine production.
PM immunization leads to faster and more intense
pulmonary and serum cytokine production as compared with
infection. In fact, higher cytokine levels could have been
expected during B. pertussis infection because of a prolonged
antigen exposure12 and higher antigen dose compared with PM
immunization with non-replicating omvPV. Therefore, weaker
cytokine responses upon an infection most likely could be
explained by the immune evasion strategies of B. pertussis, such
as the dampening of host cytokine responses.41 Extensive
comparison of early pulmonary transcriptomic profiles
induced by PM immunization obtained from this study vs.
those induced by B. pertussis infection12 demonstrated that
although both responses included genes involved in the acute
phase, PRR signaling, cytokine responses, humoral response,
and T-cell responses, these responses involved distinct genes.
Moreover, PM immunization led to faster and more intense
pulmonary gene expression, in line with cytokine profiles.
Importantly, in contrast to PM omvPV immunization, B.
pertussis colonization in the respiratory tract during infection is
a dynamic process that may lead to a distinct immune
stimulation and may explain some of the observed differences.
In general, the comparison of omvPV-induced immunity
through PM administration vs. infection-induced immunity
revealed overall comparability, notwithstanding some distinct
innate responses.
An advantage of pulmonary immunization, besides the
induction of mucosal immune responses resembling that
induced by B. pertussis infection, is that the administration is
needle-free. Currently, no pulmonary vaccines and very few
mucosal vaccines have been approved for human use. The latter
include a nasal vaccine against influenza virus and oral vaccines
against poliovirus, rotavirus, Salmonella typhi, and Vibrio
cholerae.42 Pulmonary vaccine administration in humans is in
early clinical development. Both powder inhalers43 and fluid
and nebulized vaccines have been clinically tested, the latter in
infants as young as 9 months of age.44 Intranasal vaccine
administration might also be an option as intranasal omvPV
immunization also provides protection against B. pertussis
infection19 and may be better suitable for infants. Intranasal
administration of a meningococcal OMV vaccine in humans
demonstrated induction of mucosal antibodies.45 In addition,
intranasal administration results not only in IgA antibodies in
the nasal cavity but also in the lower respiratory tract.42,46 In-
depth analysis of immune responses induced by intranasal
immunization has still to be performed with pertussis vaccines.
This study confirms the potential of omvPV as a novel
pertussis vaccine candidate.10,11,19 A different administration
route further enhanced the vaccine performance. In addition, it
is possible to include or alter more antigens, besides pertactin,
to further improve the vaccine. For example, if the presence of
Ptx is critical for the induction of efficient protection, this
could be added. A broad antigenic composition in omvPV10
may also limit the emergence of strains lacking antigens
because of vaccination-induced selection, as has occurred for
pertactin, likely in response to introduction of acellular
pertussis vaccine.
In conclusion, this study showed that PM immunization of
omvPV elicits superior local and systemic immunity against B.
pertussis infection comparedwith SC immunization.Moreover,
the adaptive immune response induced by PM omvPV
immunization is to a large extent comparable to that induced
by a B. pertussis infection. Therefore, mucosal immunization
may be key to improved protection againstB. pertussis infection
and accordingly must be considered in the development of
novel candidate pertussis vaccines. In addition to serology,
which is still the gold standard in pertussis research, a systems
vaccinology approach is invaluable in order to unravel and
understand the immunological signatures underlying vaccine-
induced immunity. Such understanding facilitates a rational
choice of a vaccine candidate and route of administration,
mitigating the risk of vaccine failure in the late stage of
development.
METHODS
Vaccineandantigens. The omvPVwas prepared11 using a genetically
modified B. pertussis B1917 strain with retained Prn.27 B. pertussis
antigens Ptx and filamentous hemagglutinin (FHA) were obtained
from Kaketsuken (Kumamoto, Japan). Prn and fimbriae (Fim) 2/3
were kindly provided by Betsy Kuipers (RIVM, Bilthoven, The
Netherlands).
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Immunization and challenge of mice. An independent ethical
committee for animal experimentation of Intravacc approved the
animal experiments. Animal handling in this study was carried out in
accordance with the guidelines provided by the Dutch Act on Animal
Experimentation. Mice within groups were randomly divided after
receiving the vaccine via a particular administration route or the B.
pertussis infection to prevent subjective bias. Ondays 0 and 28, 8-week-
old female BALB/c mice (Harlan, Horst, The Netherlands) were
immunized with omvPV containing 1 mg total protein in 50 ml
phosphate-buffered saline (PBS) for the PM route or 300 ml PBS for the
SC route. NI mice were used as a control. Pulmonary administration
was performed as described by Bivas-Benita et al.47 using a Micro-
Sprayer aerosolizer supplied with a high-pressure syringe (IA-1C and
FMJ-250; Penn-Century, Philadelphia, PA). On day 56, mice were
challenged intranasally under anesthesia (isoflurane/oxygen) with
2 10E5 colony-forming units of B. pertussis B1917 in 20 ml of THIJS
medium. The B. pertussis challenge culture was prepared as described
in the literature,12 except that bacteria were grown inTHIJSmedium.48
A study design overview with the number of animals, tissue
collection, and performed methods for each group and time point is
schematically depicted in Figure 1a.
Sample collection. Mice were anesthetized (isoflurane/oxygen) for
orbital blood collection and killed by cervical dislocation. From some
mice, the left lung lobes were incubated in RNAlater (Qiagen, Hilden,
Germany) and stored at  80 1C for microarray analysis. The right
lung lobes and trachea, used for antibody detection and colonization
assays, were homogenized in THIJSmedium using a Bio-Gen PRO200
Homogenizer (Pro Scientific, Oxford, CT) and nose lavages were
obtained (after removal of the trachea) by flushing the nosewith THIJS
medium.
Complete lungs of other mice and spleens for T- and B-cell assays,
and dLNs (bronchial LNs for PM and inguinal LNs for SC
immunization) for microarray analysis were collected in RPMI
complete medium (RPMI-1640 medium (Thermo Fisher, Waltham,
MA) supplemented with 10% fetal calf serum (GE Healthcare,
Hoevelaken, The Netherlands), 100 units penicillin, 100 units
streptomycin, and 2.92mgml 1 L-glutamine (Thermo Fisher))
and homogenized using a 70 mm cell strainer (BD Falcon, Vianen,
The Netherlands). Erythrocytes in spleen and lung samples were lysed
using homemade lysis buffer (10 g l 1 NH4CL, 1.25 g l
 1 NaHCO3,
0.125mM EDTA in dH20, pH 7.4).
Whole blood was collected in heparinized tubes (MiniCollect 1ml
LH, Greiner, Kremsmu¨nster, Austria) after which erythrocytes were
lysed using RBC lysis buffer (PharmLyse, BD; B-cell ELISpot (enzyme-
linked immunospot)) or the homemade lysis buffer (tetramer assay).
Serumwas obtained by collecting whole blood in a serum collection
tube (MiniCollect 0.8ml Z Serum Sep GOLD, Greiner). After
coagulation (10min, room temperature) and centrifugation
(10min, 3,000 g), sera were collected, aliquoted in single vials for
each analysis, and stored at  80 1C.
Colonization assays. Lung and trachea lysates, and nose lavages were
serially diluted (undiluted, 1:10, 1:100, and 1:1,000) in THIJS medium,
plated on Bordet-Gengou agar plates and incubated (5 days, 35 1C).
The colony-forming units per ml were determined using a colony
counter (ProtoCOL, Synbiosis, Cambridge, UK).
B-cell ELISpot. Filter plates (Multiscreen-HA 96-well plates, Milli-
pore, Amsterdam, The Netherlands) were coated (overnight, 4 1C)
with 5 mgml 1 Prn or 10 mgml 1 wild-type B1917 OMV. Prn and
B1917 OMVs (containing only low amounts of Prn)10 were used for
stimulation to optimally distinguish B-cell responses directed to Prn
from responses to other antigens in omvPV. Wells were coated with a
goat-anti-mouse kappa- and lambda-mixture (7mgml 1 each)
(Southern Biotech, Birmingham, AL) as positive control,
or left uncoated (PBS) as negative control. After washing with PBS,
plates were blocked with RPMI-1640 þ 2% Protifar (Nutricia,
Zoetermeer, The Netherlands) (1 h, room temperature) and washed
again.
For memory B-cell analysis, splenocytes were stimulated (5 105
cells per well, 24-well plate; 5 days, 37 1C) with 10 mgml 1 CpG ODN
1826 (Invivogen, San Diego, CA), 10mgml 1 pokeweed mitogen
(Sigma-Alderich, Zwijndrecht, The Netherlands), and Staphylococcus
aureus protein A of Cowan Strain (1:5,000; Sigma) in RPMI complete
mediumwithb-mercaptoethanol (1:25,000; Sigma) to induce antibody
secretion.49 Cells from blood (0.75 105 cells per well), lungs
(0.75 105 cells per well), spleen (5 105 cells per well), or stimulated
splenocytes (5 105 cells per well) were added to coated plates and
incubated (overnight, 37 1C). Plates were washed with PBS and PBS-T
(0.05% Tween-20) and then incubated (1 h, 37 1C) with alkaline
phosphatase-conjugated goat-anti-mouse IgA or IgG (Southern
Biotech; 1:1,000). Plates were washed with PBS, PBS-T, and tap
water. Subsequently, spot development was initiated with 0.45 mm
filtered BCIP-NBT substrate (Sigma) and stopped by extensive rinsing
with distilled water. Spots were counted with an AID iSpot reader
(Autoimmun Diagnostika, Strassberg, Germany) and indicated as
antibody-secreting cells per 5 105 cells.
Antibody measurements. Antibodies specific for OMV, Prn, FHA,
Ptx, and Fim2/3 were measured using a previously described mouse
multiplex immunoassay.10 Serum samples were diluted 1:5,000 for IgG
(subclass) and 1:100 for IgM and IgAmeasurements. Lung lysates were
diluted 1:100 for measuring IgA levels. Data were acquired with
a Bio-Plex 200, processed using Bio-Plex Manager software (v5.0,
Bio-Rad Laboratories, Veenendaal, The Netherlands), and presented
as fluorescence intensities.
Detection of Prn10–24 -specific CD4
þ T cells. Cells from erythrocyte-
lysed blood were stained (1 h, 37 1C) with Prn10–24-specific APC-
conjugated I-Ad tetramers50 (NIH Tetramer Facility, Atlanta, GA) in
RPMI complete medium. Next, cells were stained (30min, 4 1C) with
Pacific blue-conjugated anti-CD4 (Biolegend, London, UK), FITC-
conjugated anti-CD44 (BD), and LIVE/DEADFixable AquaDeadCell
Stain Kit in FACS buffer (PBS; pH 7.2, 0.5% bovine serum albumin
(Sigma Aldrich), 0.5mM EDTA (ICN Biomedicals, ICN Biomedicals,
Santa Ana, CA)). Data were acquired on a FACS Canto II (BD) and
analyzed using FlowJo software (Tree Star, Ashland, OR).
Intracellular cytokine staining. Cells from lungs and spleen were
stimulated (6 106 cells per well, 24-well plates, 3 days, 37 1C) with
1 mgml 1 Prn or 1.5 mgml 1 wild-type B1917 OMVs in Iscove’s
modified Dulbecco’s medium (IMDM) complete medium (IMDM
(Gibco), 8% fetal calf serum, 100 units penicillin, 100 units strep-
tomycin, 2.92mgml 1 L-glutamine, 20 mM b-mercaptoethanol
(Sigma)). Prn and B1917 OMVs (containing only low amounts of
Prn)10 were used for stimulation to optimally distinguish T-cell
responses directed to Prn from responses to other antigens in omvPV.
On day 3, supernatant was collected for cytokine analysis; cells were
transferred to U-bottom 96-well plates (5 105 cells per well) and
restimulated overnight using the same antigen conditions.
ICS was performed using the BD Cytofix/Cytoperm Fixation/
Permeabilization Solution Kit (BD). Cells were incubated with
10 mgml 1 Golgiplug (BD), 1 mgml 1 anti-CD28 (BD), and
1 mgml 1 anti-CD49d (BD) during the last 5 h of restimulation.
Cells were then stained with Pacific blue-conjugated anti-CD4
(Biolegend), FITC-conjugated anti-CD44 (BD), PE-Cy7-conjugated
anti-CD103 (Biolegend; only lung cells), and LIVE/DEAD Fixable
Aqua Dead Cell Stain (Invitrogen). Thereafter, cells were fixed,
permeabilized, and stained with PE-conjugated anti-IFNg (BD), APC-
conjugated anti-IL-5 (Biolegend), and PerCP-Cy5.5-conjugated anti-
IL-17A (eBioscience). Data were acquired on a FACS Canto II and
processed using FlowJo software.
Multiplex cytokine analysis. In serum and lung lysates, con-
centrations of 32 cytokines were determined using a Milliplex mouse
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Cytokine/Chemokine 32-plex luminex kit (Millipore). The con-
centration of various Th subset cytokines (IL-4, IL-5, IL-10, IL-13, IL-
17A, TNFa, and IFNg) was determined in splenic culture supernatant
using a Milliplex mouse cytokine luminex kit (Millipore). Mea-
surements and data analysis were performed with a Bio-Plex 200 and
using Bio-PlexManager software (v5.0, Bio-Rad). Results were cor-
rected for the background (IMDM complete medium control) per
mouse per stimulation per cytokine, and calculated in pgml 1.
RNA isolation and microarray analysis. RNA isolation from lung
tissue with additional determination of RNA concentrations and
integrity was performed as described previously.12 RNA from cells in
the dLNs was isolated using a MagNA Pure LC RNA Isolation High
Performance kit andMagNAPure System (Roche, Basel, Switzerland).
For lung tissue, RNA concentrates from naive and PM mice were
analyzed as individual samples, whereas those of SCmice were pooled.
Amplification, labeling, and hybridization of RNA formicroarray (HT
MG-430 PMArray Plates, Affymetrix, Santa Clara, CA) were performed
at the Microarray Department of the University of Amsterdam, The
Netherlands. Complete raw and normalized microarray data and their
MIAME compliant metadata were submitted to the Gene Expression
Omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo) with identifiers
GSE83602 and GSE83603.
Transcriptomic data analysis. Quality control and normalization of
raw Affymetrix CEL files were performed at ArrayAnalysis
(www.arrayanalysis.org)51 using the Robust Multichip Average
method52 and theMBNI customCDF (v.19).53 Analysis of normalized
data, consisting of Log2-transformed signal values for 17,856 genes,
was performed in R (www.r-project.org) andMicrosoft Excel. Analysis
of variance was applied to identify DEGs between experimental groups
before immunization and various time points afterward. The
induction or repression of individual genes was expressed as a FR by
comparing mean gene expression levels in experimental groups vs.
naive mice. The DEG criteria for transcriptome analysis on lung tissue
were po0.01 (analysis of variance), FR42.0 and for dLN po0.001,
FR 41.5. GeneMaths XT (Applied Maths, St-Martens-Latem, Bel-
gium) was used to visualize the heatmaps. Genes were arranged
according to similar expression patterns over time at which genes
exceeded FR cutoffs. Principal component analysis based on
expression profiles of all DEGs was performed in R. Functional
enrichment based on GO-BP and KEGGwas performed using ORA in
DAVID. Involvement of type I and II IFN signaling pathways was
analyzed using the Interferome database (http://www.interferome.org/
interferome/home.jspx).54
Gene network analysis. To construct a gene-function network, ORA
results and additional text mining were used to determine genes
associated with five modules: acute phase, cytokine response, humoral
response, PRR signaling, and T-cell responses. Interactions between
genes were determined using STRING (http://string.embl.de/) with
high confidence (0.700) and using co-occurrence, coexpression,
experiments, databases, and text mining as types of evidence. Gene-
function associations and gene–gene interactions were combined into
one network file. The network visualization was performed using
Cytoscape (v.2.8.3; http://www.cytoscape.org/).
Immunoproteomic profiling. To identify antigen specificity of
antibody responses, electrophoresis combined with western blotting
and liquid chromatography–mass spectrometry analysis were per-
formed.10 The B. pertussis for lysate and omvPV were cultivated and
harvested under similar conditions (defined medium, optical density,
similar strain) to ensure overlap of all antigens. Gels were blotted with
respectively 10–15 mg and 25 mg protein of a B. pertussis (B1917) lysate
for one- and two-dimensional electrophoresis. Blots were treated with
diluted sera (1:100) or diluted lung lysates (1:10–1:50) before
immunostaining with IR-800-labeled goat-anti-mouse IgG or IgA.
Blots were scanned using an Odyssey infrared imager (Westburg,
Leusden, The Netherlands) and analyzed with Delta2D (v.4.5,
Decodon, Greifswald, Germany).
Statistics. To determine significance of intergroup differences for
B-cell ELISpot, T-cell ICS, and T-cell tetramer analysis, Mann–
Whitney t-test was used. Data from cytokine, antibody, and colo-
nization assays were log-transformed and statistically tested (t-test). P-
values of r0.05 were considered as significant differences.
SUPPLEMENTARYMATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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